Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression

Oncotarget

Volumn 7, Issue 26, 2016, Pages 39894-39906

  Verma, Vivek ^a,d   Kim, Young ^a   Lee, Min Cheol ^a   Lee, Jae Tae ^b   Cho, Sunghoon ^c   Park, In Kyu ^a   Min, Jung Joon ^a   Lee, Je Jung ^a,c   Lee, Shee Eun ^a,c   Rhee, Joon Haeng ^a  

^a Chonnam National University Medical School   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Chonnam National University   (South Korea)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Biomatrices; Dendritic cells; Immunotherapy; Tumor

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; PEPTIDE VACCINE; CANCER VACCINE; IMMUNOSUPPRESSIVE AGENT; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BIODEGRADABILITY; BIOMATRIX ENTRAPPED DENDRITIC CELL; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURGERY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE SCAFFOLD; TUMOR REGRESSION; UTERINE CERVIX CANCER; ANIMAL; C57BL MOUSE; COCULTURE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PHENOTYPE; SPLEEN; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; COCULTURE TECHNIQUES; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS; PHENOTYPE; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84982988056     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9529     Document Type: Article

References (39)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64:252-271.
2. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci USA. 2013; 110:E415-424.
3. Aliperti LA, Predina JD, Vachani A, Singhal S. Local and systemic recurrence is the Achilles heel of cancer surgery. Ann Surg Oncol. 2011; 18:603-607.
4. de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, et al. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. J Transl Med. 2014; 12:209.
5. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39:38-48.
6. Edele F, Dudda JC, Bachtanian E, Jakob T, Pircher H, Martin SF. Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route. PLoS One. 2014; 9:e105266.
7. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 2011; 4:361-375.
8. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, Fiering S, Conejo-Garcia JR. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012; 209:495-506.
9. Chen L, Fabian KL, Taylor JL, Storkus WJ. Therapeutic Use of Dendritic Cells to Promote the Extranodal Priming of Anti-Tumor Immunity. Front Immunol. 2013; 4.
10. Angel CE, Chen CJ, Horlacher OC, Winkler S, John T, Browning J, MacGregor D, Cebon J, Dunbar PR. Distinctive localization of antigen-presenting cells in human lymph nodes. Blood. 2009; 113:1257-1267.
11. Chtanova T, Han SJ, Schaeffer M, van Dooren GG, Herzmark P, Striepen B, Robey EA. Dynamics of T cell, antigen-presenting cell, and pathogen interactions during recall responses in the lymph node. Immunity. 2009; 31:342-355.
12. Christopher J. Kirk DH-OCaJJM. The Dynamics of the T-Cell Antitumor Response: Chemokine-secreting Dendritic Cells Can Prime Tumor-reactive T Cells Extranodally. Cancer Res. 2001; 61:8794-8802.
13. Wang Y, Sui Y, Kato S, Hogg AE, Steel JC, Morris JC, Berzofsky JA. Vaginal type-II mucosa is an inductive site for primary CD8(+) T-cell mucosal immunity. Nat Commun. 2015; 6:6100.
14. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 2005; 65:5958-5964.
15. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. Journal of Clinical Investigation. 2004; 113:774-783.
16. Ma L, Cheung KC, Kishore M, Nourshargh S, Mauro C, Marelli-Berg FM. CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo. J Immunol. 2012; 189:4104-4111.
17. Stoll S, Delon J, Brotz TM, Germain RN. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science. 2002; 296:1873-1876.
18. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol. 2003; 4:579-585.
19. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10:475-480.
20. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19:1423-1437.
21. dVI JM, KDJE B, Scharenborg N M J LW, Diepstra JHS, van Muijen GNP, Strijk SP, Ruers TJ, Boerman OC, Oyen WJG, Adema GJ, Punt CJA, G FC. Effective Migration of Antigen-pulsed Dendritic Cells to Lymph Nodes in Melanoma Patients Is Determined by Their Maturation State. Cancer Res. 2003; 63:12-17.
22. Youk H, Lim WA. Sending mixed messages for cell population control. Cell. 2014; 158:973-975.
23. Stevens KR, Ungrin MD, Schwartz RE, Ng S, Carvalho B, Christine KS, Chaturvedi RR, Li CY, Zandstra PW, Chen CS, Bhatia SN. InVERT molding for scalable control of tissue microarchitecture. Nat Commun. 2013; 4:1847.
24. Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2014.
25. Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G, Mooney DJ. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2015; 33:64-72.
26. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, Desmarais C, Boyer JD, Tycko B, Robins HS, Clark RA, Trimble CL. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014; 6:221ra213.
27. Neyt K, Perros F, Geurtsvan Kessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012; 33:297-305.
28. Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, Bonehill A. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther. 2012; 20:1063-1074.
29. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood. 2011; 118:499-509.
30. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. Annu Rev Immunol. 2008; 26:627-650.
31. Geurtsvan Kessel CH, Willart MA, Bergen IM, van Rijt LS, Muskens F, Elewaut D, Osterhaus AD, Hendriks R, Rimmelzwaan GF, Lambrecht BN. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med. 2009; 206:2339-2349.
32. Suematsu S, Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat Biotechnol. 2004; 22:1539-1545.
33. Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Molecular Therapy. 2014; 1:14001.
34. Gorodetsky R, Vexler A, An J, Mou X, Marx G. Haptotactic and growth stimulatory effects of fibrin(ogen) and thrombin on cultured fibroblasts. Journal of Laboratory and Clinical Medicine. 1998; 131:269-280.
35. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010; 62:726-759.
36. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol. 2005; 6:1198-1205.
37. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009; 6:e1.
38. Kayo Inaba WJS, Ralph M. Steinman, Nikolaus Romani, Schuler G. (1998). Isolation of Dendritic Cells. Current Protocols in Immunology: John Wiley & Sons, Inc., pp. Unit 3.7.
39. Predina JD, Judy B, Fridlender ZG, Aliperti LA, Madajewski B, Kapoor V, Cheng G, Quatromoni J, Okusanya O, Singhal S. A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biology & Therapy. 2012; 13:745-755.